Core Viewpoint - Four Seasons Pharmaceutical (00460) has seen its stock price increase by over 5% following the approval of its innovative drug, Pyrotinib tablets (brand name: XuanYueNing), for a new indication in the treatment of HR+/HER2- advanced breast cancer in China [1] Group 1: Company Developments - On March 3, Four Seasons Pharmaceutical announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the new indication of Pyrotinib tablets in combination with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer [1] - This approval marks the third indication for Pyrotinib in China, following its previous approvals for use in combination with Fulvestrant and as a monotherapy [1] - Pyrotinib is now the first and only drug in China to cover the entire treatment course for HR+/HER2- advanced breast cancer across first-line, second-line, and later lines, significantly expanding patient coverage and enhancing clinical value [1] Group 2: Market Impact - The approval is expected to effectively increase the drug's accessibility and clinical value, providing strong support for future sales growth [1] - As of the report, Four Seasons Pharmaceutical's stock price rose by 5.19%, reaching HKD 1.42, with a trading volume of HKD 19.4691 million [1]

Core Viewpoint - The announcement by Four Seasons Pharmaceutical (00460) regarding the inclusion of its innovative drug Pirlosil (brand name: XuanYueNing) in the 2025 National Basic Medical Insurance Directory is expected to enhance the drug's affordability and accessibility for patients, positively impacting its market promotion and sales growth [1] Group 1 - Four Seasons Pharmaceutical's subsidiary, XuanZhu Biotechnology, has developed the innovative drug Pirlosil, which will be included in the 2025 National Basic Medical Insurance Directory [1] - The 2025 National Basic Medical Insurance Directory will officially take effect on January 1, 2026 [1] - The inclusion in the insurance directory is anticipated to facilitate the market expansion of Pirlosil, thereby benefiting the long-term operational development of XuanZhu Biotechnology [1] Group 2 - XuanZhu Biotechnology plans to actively cooperate in implementing the insurance policy and will continue to work on hospital access and expanding market coverage [1] - The goal is to enhance patient access to the medication continuously [1]

Core Viewpoint - The announcement indicates that Xuanzhu Biotech-B (02575) has successfully included its self-developed innovative drug, Pirlosil, in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which will take effect on January 1, 2026 [1] Group 1 - The inclusion of Pirlosil (brand name: Xuanyuening) in the 2025 National Basic Medical Insurance Directory will enhance its affordability and accessibility for patients [1] - This development is expected to promote the market penetration and increase the sales scale of the drug, positively impacting the company's long-term operational growth [1] - The company plans to actively cooperate in implementing the insurance policy, continue hospital access initiatives, expand core markets, and increase market coverage to improve patient access to medication [1]

Core Viewpoint - The announcement by Xuan Bamboo Biotech-B (02575) regarding the inclusion of its innovative drug Pirlosil (brand name: Xuan Yuening) in the 2025 National Basic Medical Insurance Directory is a significant development that will enhance the drug's affordability and accessibility for patients, positively impacting the company's long-term operational growth [1] Group 1 - The innovative drug Pirlosil has been included in the 2025 National Basic Medical Insurance Directory, which will be officially implemented on January 1, 2026 [1] - This inclusion is expected to facilitate the market promotion and sales growth of Xuan Yuening, benefiting the company's long-term development [1] - The company plans to actively cooperate in the implementation of the medical insurance policy, continue to promote hospital access, expand core markets, and increase market coverage to enhance patient accessibility to the medication [1]